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Rationale, application and clinical qualiﬁcation for
NT-proBNP as a surrogate end point in pivotal clinical
trials in patients with AL amyloidosis
G Merlini1,9, I Lousada2, Y Ando3, A Dispenzieri4, MA Gertz4, M Grogan4, MS Maurer5, V Sanchorawala6, A Wechalekar7, G Palladini1
and RL Comenzo8,9
Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In
patients with AL amyloidosis, LC aggregates progressively accumulate in organs, resulting in organ failure that is particularly lethal
when the heart is involved. A signiﬁcant obstacle in the development of treatments for patients with AL amyloidosis, as well as for
those with any disease that is rare, severe and heterogeneous, has been satisfying traditional clinical trial end points (for example,
overall survival or progression-free survival). It is for this reason that many organizations, including the United States Food and Drug
Administration through its Safety and Innovation Act Accelerated Approval pathway, have recognized the need for biomarkers as
surrogate end points. The international AL amyloidosis expert community is in agreement that the N-terminal fragment of the pro-
brain natriuretic peptide (NT-proBNP) is analytically validated and clinically qualiﬁed as a biomarker for use as a surrogate end point
for survival in patients with AL amyloidosis. Underlying this consensus is the demonstration that NT-proBNP is an indicator of
cardiac response in all interventional studies in which it has been assessed, despite differences in patient population, treatment
type and treatment schedule. Furthermore, NT-proBNP expression is directly modulated by amyloidogenic LC-elicited signal
transduction pathways in cardiomyocytes. The use of NT-proBNP will greatly facilitate the development of targeted therapies for AL
amyloidosis. Here, we review the data supporting the use of NT-proBNP, a biomarker that is analytically validated, clinically
qualiﬁed, directly modulated by LC and universally accepted by AL amyloidosis specialists, as a surrogate end point for survival.
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INTRODUCTION
Amyloid light-chain (LC) amyloidosis (AL amyloidosis), a rare,
progressive and fatal disease, is the most common form of
systemic amyloidosis,1,2 and it affects an estimated 8–12 per
1 000 000 persons annually.3,4 Systemic amyloidosis is character-
ized by the accumulation of abnormal, misfolded protein
(amyloid) in various tissue and organs that produce patient-
speciﬁc clinical manifestations depending on the organ impacted.
Progressive amyloid deposition and proteotoxic effects of amyloid
proteins lead to organ failure, which is especially catastrophic
when the heart is affected, and is the primary cause of death.1,5 As
many as 70% of patients with AL amyloidosis have predominantly
cardiac amyloid deposition.2,5 The prevalence of all types of
cardiac amyloidosis is assumed to be underestimated because of
missed diagnoses, given that the symptoms of cardiac amyloidosis
often mimic those of other far more common conditions.6–8
There are no approved therapies for AL amyloidosis. That said,
frequently used treatment options, such as high-dose chemotherapy
in combination with autologous stem cell transplantation, alkylating
agents, steroids, proteasome inhibitors and/or immunomodulatory
drugs, reduce production of the amyloid-forming precursor
protein, immunoglobulin LC, by targeting plasma cells.1,2,9,10
Overall, plasma cell-directed therapies, also called source thera-
pies, can induce a reduction in the concentration of the toxic LC
by ⩾ 50% (partial response or better) in ~ 60% of patients, and this
translates into cardiac or renal response, or both, in ~ 20–35% of
patients. Cardiac response translates into substantial survival
beneﬁt.2,10,11
BIOMARKERS AS SURROGATE END POINTS FOR RARE
DISEASES
A signiﬁcant barrier to therapeutic development is posed by all
diseases that are serious, heterogeneous and rare; for such
diseases, traditional trials with clinical end points are difﬁcult, and
sometimes impossible, to conduct.12 It is for this reason that the
use of biomarkers as surrogate end points was proposed by the
United States Food and Drug Administration (FDA) with its Safety
and Innovation Act Accelerated Approval pathway12,13 to hasten
the approval of new treatments. Furthermore, this position was
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recently promoted by the FDA: ‘The path to development of
promising therapeutics can be enabled by the availability of
biomarkers that are analytically validated and clinically qualiﬁed
for a speciﬁc context of use’.14
The international AL amyloidosis expert community is in
agreement that the N-terminal fragment of the pro-brain
natriuretic peptide (NT-proBNP) is analytically validated and
clinically qualiﬁed as a biomarker for use as a surrogate end point
for survival in patients with AL amyloidosis. This consensus is
supported by the consistent demonstration of the predictive value
of NT-proBNP in all intervention trials to date, which we review
here, and is especially striking in light of differences in study
design, treatment regimens or combinations of treatment regi-
mens, treatment class, patient population and geographic
location. The reliability of NT-proBNP as a biomarker results from
a direct intracellular pathway connecting the amyloid-forming
precursor protein, immunoglobulin LC, to the induction of kinases
known to promote BNP expression, and it makes the use of
NT-proBNP, a robust surrogate for survival unique from other
applications (for example, heart failure) in which inconsistencies
have justiﬁably warranted apprehension. This rare and fatal
disease should be considered a priority for expediting new
treatments. In line with the Accelerated Approval pathway,13 a
surrogate end point must be reasonably likely to predict a
treatment’s clinical beneﬁt so that it will be considered validated
and acceptable by regulatory authorities. In accordance with the
FDA’s criteria for Accelerated Approval, the following qualifying
criteria for using a surrogate end point are met for AL amyloidosis:
‘…treats a serious condition…’—this is relevant for the substantial
morbidity and mortality associated with AL amyloidosis.
‘…demonstrates an effect on a surrogate endpoint that is
reasonably likely to predict clinical beneﬁt or on a clinical
endpoint that can be measured earlier than irreversible
morbidity or mortality (IMM) that is reasonably likely to predict
an effect on IMM…’—hematologic response, a commonly used
efﬁcacy measure for AL amyloidosis patients, may not capture
the speciﬁc impact on heart dysfunction, which causes death.
Consistent evidence from several independent clinical trials
uniformly supports that NT-proBNP not only reasonably, but
highly likely predicts clinical beneﬁt to the heart. The use of a
survival end point requires unacceptably extended trial
durations for initial approval but could be conﬁrmatory.
Without acceptance of surrogate end points for survival, a
primary obstacle of AL amyloidosis clinical trials is their long
duration and large study size, necessary because of the need for
end points to demonstrate efﬁcacy (foe example, overall survival
and organ failure) with appropriate statistical power. Furthermore,
the availability of several effective lines of plasma cell-directed
therapy makes it difﬁcult to evaluate the impact of a speciﬁc
treatment on overall survival, and signiﬁcant morbidity caused by
organ dysfunction makes it difﬁcult to deﬁne progression-free
survival. Acceptance by the regulatory authorities of this
important surrogate will accelerate drug development by
facilitating more rapid clinical development of molecules and will
standardize study designs evaluated in clinical trials (for example,
treatment dose and duration, patient inclusion criteria and
interpretation of multiple treatments). This will lead to more
drug-industry investment into the study of AL amyloidosis. At
present, ‘source therapies’ are being used off-label, and few
manufacturers are pursuing regulatory approval because of the
long development time, difﬁcult trial design and signiﬁcant
investment required for such a small population.
Although controlling the source of the amyloid precursor
protein and factoring hematologic response into efﬁcacy mea-
sures is important, they are of limited long-term value to patients
in the absence of organ improvement.15 For this reason, using
NT-proBNP as a surrogate end point for pivotal clinical trials in
patients with AL amyloidosis will advance therapeutic treatments
that save lives. Here, we present the data and rationale for the use
of NT-proBNP, a biomarker that is analytically validated, clinically
qualiﬁed, directly modulated by LC-elicited signal transduction
pathways in cardiomyocytes and accepted by AL amyloidosis
specialists as a surrogate end point for survival.
CARDIAC AMYLOIDOSIS
In AL amyloidosis, misfolded LCs predominantly affect the heart
(~70% of patients), kidneys (70% of patients) or both, but can also
affect the liver, gastrointestinal tract, soft tissue, and peripheral
and autonomic nervous systems (o20% patients each).1,10,16 The
extent of cardiomyopathy is the most important determinant of
outcome in patients with systemic amyloidosis.2,5,17 As mentioned,
no therapies have been speciﬁcally approved for the treatment of
patients with AL amyloidosis, and optimal treatment regimens
remain undeﬁned.9,18
Extracellular amyloid deposits in the heart create anatomic
restrictions that contribute to cardiac dysfunction.19 Amyloid-
forming LCs also cause rapid and direct myocardial toxicity,20,21
eliciting oxidative damage,22,23 possibly through interactions with
mitochondrial proteins.24 Amyloid LCs puriﬁed from patients with
amyloid cardiomyopathy induce p38 mitogen-activated protein
kinase (MAPK) signaling,25 resulting in oxidative stress, impaired
excitation-contraction coupling22,26 and, eventually, cardiomyo-
cyte death.25,26
Mayo Clinic investigators recently reported that hematologic
response alone is not necessarily adequate to result in clinical
beneﬁt, and that early organ response predicts improved overall
survival after successful therapy in AL.15 The development of
therapies designed to decrease levels of circulating precursor, clear
toxic cardiac aggregates and accelerate the clearance of amyloid
deposits addresses a critical unmet need to reverse or attenuate
cardiomyopathy in patients with AL amyloidosis. The use of
NT-proBNP will facilitate the emergence of such novel therapies.
BIOLOGICAL SIGNIFICANCE OF NT-PROBNP
NT-proBNP has emerged as an analytically validated, gold
standard biomarker for the determination of cardiovascular risk
and disease.27 In some patients, NT-proBNP assessment may
facilitate a better diagnosis than physician review of patient
history and other laboratory ﬁndings.28,29 Moreover, the response
of NT-proBNP after intervention is often used in clinical trials to
assess outcome and cardiac progression. NT-proBNP has been
clinically qualiﬁed to a great extent in AL amyloidosis, and AL
amyloidosis specialists agree that it predicts cardiac response and
improved clinical outcome after intervention. Thus, NT-proBNP, in
contrast to other cardiac markers (for example, cardiac troponins),
is the focus of this article.
BNP is a myocyte-secreted hormone that maintains ﬂuid
homeostasis in the body through natriuretic, diuretic and
vasodilatory effects. BNP is secreted in response to ventricle
distension and stretching caused by volume expansion and
pressure overload.30,31 Cardiomyocytes synthesize a pre-
propeptide (preproBNP; 134 amino acids), which is cleaved to
the propeptide (proBNP; 108 amino acids). After secretion, proBNP
is cleaved to the active hormone BNP (amino acids 77–108) and
the biologically inactive peptide NT-proBNP (amino acids
1–76).31,32 Notably for AL amyloidosis, MAPK signaling mediates
BNP transcription,33–35 supporting a direct connection between LC
cardiotoxic effects with induced MAPK signaling and BNP levels.
This direct modulation of BNP synthesis by cardiotoxic LC amyloid
precursor is distinct from the processes proposed to elicit BNP
secretion in other cardiovascular diseases and makes BNP levels
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directly reﬂective of the LC-induced cardiac pathology in AL
amyloidosis. Ventricular dysfunction is indicated by increased
serum BNP and NT-proBNP, which are secreted at a 1:1 equimolar
basis.32 In the circulatory system, NT-proBNP has a longer half-life
than BNP (2 h vs 22 min) and is subject to renal clearance.30,32
Measurement of NT-proBNP is a robust, standardized laboratory
test than can be easily and rapidly performed worldwide
(1 h using electrochemiluminescence immunoassay).36 European
Cardiology Society guidelines for the diagnosis and treatment of
acute and chronic heart failure include measurement of natriuretic
peptides among the essential initial investigations, reporting that
a normal natriuretic peptide level in an untreated patient virtually
excludes signiﬁcant cardiac disease, making echocardiography
unnecessary.29 Furthermore, in their recent document deﬁning
cardiovascular end points for clinical trials, the American College
of Cardiology/American Heart Association included NT-proBNP/
BNP as laboratory evidence supporting the diagnosis of worsening
heart failure.37
Circulating NT-proBNP levels increase with patient age and
renal insufﬁciency, are higher in women than men and are
generally lower in obese patients because of the presence of
NT-proBNP receptors on adipocytes and the production of
neprilysin in adipose tissue. On the basis of the biological
variability, resulting in a critical difference/reference change value
of ~ 25% of circulating NT-proBNP,38,39 clinically meaningful
response has been deﬁned as a 430% decrease of NT-proBNP,
a reduction of ⩾ 300 ng/l (35.4 pmol/l) in patients with ⩾ 650 ng/l
(76.7 pmol/l) baseline NT-proBNP.11,40
No clear superiority of BNP compared with NT-proBNP has been
established in the biomarker ﬁeld; however, studies performed in
patients with AL amyloidosis have primarily used NT-proBNP. This
might be because NT-proBNP has a longer half-life, is more sensitive
and more stable (for example, can be performed on frozen serum)
than BNP, which requires stricter pre-analytical requirements.
Measuring circulating NT-proBNP is more rapid, more repro-
ducible, more affordable and more accessible than evaluations
that require specialized equipment, procedures (for example,
echocardiography) and trained personnel,29 and may allow for the
detection of meaningful cardiovascular responses in advance of
morphologic changes found on echocardiography.41 NT-proBNP is
the most sensitive marker of cardiac involvement in AL
amyloidosis; it has 100% sensitivity for detecting cardiac involve-
ment estimated by clinical signs, electrocardiography and
echocardiography using the validated cutoff of 332 ng/l
(0.33 mg/ml or 39.2 pmol/l).42
APPLICATION OF CARDIAC BIOMARKERS TO PATIENTS WITH
AL AMYLOIDOSIS
Several studies demonstrate that cardiac biomarkers, particularly
NT-proBNP, are powerful predictors of prognosis in AL
amyloidosis.42,43 Current staging systems for this disease are
based on serum levels of NT-proBNP, cardiac troponin T and the
concentration of circulating amyloidogenic-free LCs.44 In addition
to the relevance of NT-proBNP in prognostic stratiﬁcation at
baseline, changes in NT-proBNP concentration after therapy
predict clinical outcomes for patients. Speciﬁcally, NT-proBNP
response or progression predicts attenuation or progression of
cardiac dysfunction, with signiﬁcant impact on survival.11
BASELINE NT-PROBNP AS A PROGNOSTIC FACTOR
Nine studies42,45–52 demonstrate that baseline NT-proBNP level
predicts clinical outcome in patients with newly diagnosed AL
amyloidosis. Palladini et al.42 ﬁrst reported an association between
baseline NT-proBNP levels with cardiac involvement and survival
in 152 patients with AL amyloidosis (Figure 1). In separate
publications, Dispenzieri et al.53 demonstrated that baseline
NT-proBNP levels predicted survival in 242 patients with newly
diagnosed amyloidosis and in 98 patients before they underwent
autologous stem cell transplantation (ASCT).51 Kristen et al.50
demonstrated that baseline NT-proBNP level was an independent
predictor of survival in 163 patients with AL amyloidosis. In an
analysis of 1998 patients seen over a 30-year period at the Mayo
Clinic compared with 313 contemporary patients, Kumar et al.45
reported that NT-proBNP levels consistently identiﬁed patients at
risk for early death despite improvements in survival during the
same period. Wechalekar et al.52 demonstrated that presenting
NT-proBNP correlated with survival in a group of 346 patients with
newly diagnosed AL amyloidosis who subsequently were treated
with hematologic therapies. Kristen et al.46 showed that baseline
NT-proBNP level was a univariate predictor of survival in 185
patients with AL amyloidosis. Banypersad et al.47 demonstrated, in
100 patients with AL amyloidosis, that cardiac disease revealed by
nuclear magnetic resonance imaging correlated with NT-proBNP
levels. Kristen et al.48 conﬁrmed that risk stratiﬁcation associated
with both NT-proBNP and cardiac troponin T predicted 1-year
mortality in 125 patients with AL amyloidosis. These 9 indepen-
dent studies in 3722 treatment-naive patients show that NT-
proBNP responses consistently reﬂect changes in cardiac function
and predict survival in patients with AL amyloidosis.
NT-PROBNP RESPONSE AFTER INTERVENTION PREDICTS
CLINICAL OUTCOME
In the context of interventional therapy, 5 large independent
studies11,49,54–56 have established that the NT-proBNP response,
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deﬁned as a decrease in NT-proBNP of 430% and 4300 ng/l
(35.4 pmol/l) in evaluable patients (those whose baseline
NT-proBNP levels were ⩾ 650 ng/l; 76.7 pmol/l), predicts clinical
outcome and survival. NT-proBNP is a survival marker indepen-
dent of therapy type, treatment class, or regimen; these studies
represent patients treated with 9 different combinations of
therapies and 3 different individual therapies, which include
chemotherapies and ASCT as well as steroids, immunomodulatory
drugs, proteasome inhibitors, and alkylating agents (Table 1).
Palladini et al.54 documented, in 51 patients with cardiac AL
amyloidosis treated with melphalan plus dexamethasone (MDex),
thalidomide plus dexamethasone (TDex), dexamethasone (Dex),
melphalan plus prednisone (MP) or thalidomide (T), that achieve-
ment of NT-proBNP response predicted both overall survival and
progression-free survival (Figure 2). Subsequently, Kastritis et al.55
showed that the post-treatment NT-proBNP (and BNP) response
independently predicted survival in 94 patients with AL amyloi-
dosis treated with bortezomib (Bor) or Bor plus dexamethasone
(BDex). Palladini et al.49 demonstrated that post-treatment
NT-proBNP response independently predicted patient survival in
a study of 113 patients with AL amyloidosis treated primarily with
MDex, Dex, cyclophosphamide plus thalidomide and dexametha-
sone (CyTDex) or ASCT. Kastritis et al.56 reported that NT-proBNP
response predicted survival in 85 patients with AL amyloidosis
treated with BDex or with L-based or risk-adapted BDex. On the
basis of these results, in 2012 the International Society ofT
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Figure 2. Overall (a) and progression-free (b) survival with respect to
NT-proBNP response in Palladini et al.54 Adapted with permission
from Palladini et al.54
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Amyloidosis established and validated NT-proBNP response as an
indicator of organ response and as a surrogate marker of survival
in AL amyloidosis. NT-proBNP response predicted a signiﬁcant
survival beneﬁt both in testing (n= 816) and in validation (n= 374)
populations treated primarily with MDex, T-based, lenalidomide
(L)-based, Bor-based, Dex, MP or ASCT treatments (Figure 3).11
Notably, this international study in 1190 patients failed to show
any survival beneﬁt of ⩾ 2-mm reduction in the thickness of the
cardiac interventricular septum, which had been used as a
criterion for cardiac response.56
Overall, these 5 independent studies11,48,54–56 in 1482 patients
after interventional treatment show that NT-proBNP responses
consistently reﬂect changes in cardiac function and predict
survival in patients with AL amyloidosis. However, these studies
were retrospective. Prospectively, the response criteria are being
used in an ongoing phase 3 study comparing MDex with MBDex
(NCT01277016). Although the study is not yet complete and the
number of evaluable patients is limited, the preliminary outcome
analysis indicates that NT-proBNP response translates into a
signiﬁcant survival beneﬁt (Figure 4).
AL amyloidosis is an exceedingly rare disease. To put it in
context, AL amyloidosis with cardiac involvement is diagnosed in
~ 3000 new patients each year in the US57 The post-intervention
validation sample set of 5 studies11,48,54–56 represents roughly 49%
of all new diagnoses per year. Even in multiple myeloma, ~ 14 000
patients would be needed to reach the average number of new
diagnoses this year in the US for a similar validation set.
In patients with both renal and cardiac involvement, reductions
in glomerular ﬁltration rate can inﬂuence NT-proBNP levels. In a
study of 248 such patients, stratiﬁcation by glomerular ﬁltration
rate (⩾60 ml/min/1.73 m2; o60 and ⩾ 15 ml/min/1.73 m2; or
o15 ml/min/1.73 m2) revealed that though decreasing glomeru-
lar ﬁltration rate required a higher threshold for detecting heart
involvement and predicting survival, NT-proBNP predicted survival
in patients with glomerular ﬁltration rates⩾ 15 ml/min/1.73 m2.58
Although several cardiac biomarkers and imaging techniques
have been reported to have a prognostic value, none have been
validated as surrogate markers of cardiac response and clinical
outcome in patients with AL amyloidosis. There is no clear
correlation between reductions in NT-proBNP with improvements
in cardiac anatomy,54 which may reﬂect potentially differing time
courses in detectable changes in cardiac structure compared with
hormone secretion and/or a distinct role served by LC in the
modulation of BNP expression through a direct cytotoxic
mechanism. More reﬁned echocardiographic assessment, such
as tissue Doppler imaging and strain rate imaging, may ultimately
add to the prognostic discrimination based on biomarkers at
baseline, but this application requires systematic study in patients
with cardiac amyloidosis, and there is no useful precedent for
monitoring response to therapy (reviewed in studies by Gertz
et al.59 and Falk et al.60). Similarly, recent studies61 have proposed
cardiac magnetic resonance imaging as an additional prognostic
tool in cardiac AL amyloidosis, but no study has yet explored
cardiac magnetic resonance imaging in response assessment.
Notable additional strengths of NT-proBNP assessment are its
robust standardization, reproducibility, ease, speed and low-cost
compared with more expensive and complex imaging techniques
that are frequently operator dependent.
Although other biomarkers (including high-sensitivity troponin62
and novel biomarkers such as ST2,63 GDF-15,64 mid-regional pro-
adrenomedullin65 and osteoprotegerin66) measured at diagnosis
are prognostic factors in patients with AL amyloidosis, they have
not yet been predictive of survival based on response after
interventional treatment. More evidence is needed to establish
their potential value. Only NT-proBNP response after several
different classes of treatment indicated patient outcome and
could be used as a marker of response. Increased cardiac troponin
indicated disease progression and poor survival in patients with
AL amyloidosis, but the role for troponin in the deﬁnition of
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Figure 4. Survival according to NT-proBNP response in an ongoing
phase 3 trial comparing melphalan-dexamethasone with melphalan-
bortezomib-dexamethasone (NCT01277016).
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response remains less established.11,49,62,66,67 Finally, NT-proBNP
should continue to be evaluated for use in assessing cardiac
response in patients with both mutated and wild-type cardiac
transthyretin amyloidosis.
SUMMARY AND CONCLUSION
NT-proBNP is a unique biomarker of cardiac amyloid involvement
in patients with AL amyloidosis. It is of fundamental importance
for establishing diagnosis, prognosis, and response to therapy in
AL cardiomyopathy. This formidable clinical impact derives from
the direct regulation of NT-proBNP levels by pathologic processes
downstream of cardiac LC signaling (that is, MAPK activation),
making NT-proBNP an unambiguous marker of amyloid cardiac
disease. The use of NT-proBNP as a surrogate efﬁcacy end point
for AL amyloidosis trials using current, validated deﬁnitions of
response is not controversial. NT-proBNP level should be widely
adopted to evaluate the effectiveness of new treatments targeting
cardiac dysfunction in patients with AL amyloidosis as an accepted
primary outcome. Experts agree that NT-proBNP is the only
surrogate end point for survival after treatment, and lowering NT-
proBNP and achieving NT-proBNP response are the ultimate
treatment objectives. Overall survival as an end point requires a
larger study population and a longer assessment period; a trial
using NT-proBNP could be half as long (Figure 5). The use of this
end point is particularly important to minimize treatment-related
toxicity and mortality and to conduct systematic clinical research
more rapidly.
A recent meta-analysis68 of the impact of biomarker-based
strategies on oncology drug development from clinical trials that
led to FDA approval supported the safety and improved efﬁcacy
outcomes in FDA-approved anticancer agents using biomarker-
based tactics. This approach is now feasible and necessary in AL
amyloidosis. Now is a pivotal moment for many novel drugs in the
pipeline that promise to address unmet needs in this rapidly
evolving, but curable, disease. We owe it to our patients to rapidly
assess the efﬁcacy of new drugs. The data presented here
establish that the NT-proBNP response, deﬁned as a decrease in
NT-proBNP of 430% and 4300 ng/l (35.4 pmol/l), predicts
clinical outcome and survival and is a validated and qualiﬁed
surrogate marker of efﬁcacy for interventions for patients with AL
amyloidosis.
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